Get to know and reach out to the experts at Profil.

Short Bio

Oliver is a physician with a clinical background in internal medicine and 14 years of experience in the development, conduct and evaluation of clinical research projects in the field of diabetes.
He takes particular interest in insulin pharmacology and methods of metabolic research.
He is a scientific study advisor at Profil in Neuss.

Publications

Here are Oliver's recent publications:

• Leohr J, Klein O, Heise T, Zijlstra E, Bue-Valleskey JM, Suriyapperuma S, Jarrett R, James D, Case M, Waters D, Pratt E, Linnebjerg H. Characterisation of steady-state pharmacokinetics and glucodynamics of once-weekly insulin efsitora alfa in individuals with type 2 diabetes. Diabetes Obes Metab. 2026 May;28(5):4010-4018. doi: 10.1111/dom.70585. Epub 2026 Feb 23. PMID: 41725424; PMCID: PMC13071231. 
• Garhyan P, Pratt E, Klein O, Famulla S, Zijlstra E, Lalonde A, Swinney M, Kazda C, Dassau E. Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes. J Diabetes Sci Technol. 2023 Mar;17(2):274-282. doi: 10.1177/19322968221145200. Epub 2022 Dec 28. PMID: 36575993; PMCID: PMC10012385. 
• Heise T, Chien J, Beals JM, Benson C, Klein O, Moyers JS, Haupt A, Pratt EJ. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023 Apr;25(4):1080-1090. doi: 10.1111/dom.14956. Epub 2023 Jan 9. PMID: 36541037. 
• Plum-Mörschel L, Klein O, Singh G, Murugesan SMN, Marwah A, Sharma N, Panda J, Loganathan S, Lakshmi GC, Athalye SN. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study. Diabetes Obes Metab. 2022 Sep;24(9):1819-1828. doi: 10.1111/dom.14768. Epub 2022 Jun 6. PMID: 35589611; PMCID: PMC9543887. 
• Leohr J, Kazda C, Liu R, Reddy S, Dellva MA, Matzopoulos M, Loh MT, Hardy T, Klein O, Kapitza C. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study. Diabetes Obes Metab. 2022 Feb;24(2):187-195. doi: 10.1111/dom.14561. Epub 2021 Oct 27. PMID: 34605142; PMCID: PMC9297897. 
• Leohr J, Dellva MA, LaBell E, Coutant DE, Klein O, Plum-Moerschel L, Zijlstra E, Linnebjerg H.
  Pharmacokinetic and glucodynamic responses of ultra rapid lispro vs lispro across a clinically relevant range of subcutaneous doses in healthy subjects.
  Clin Ther 42: 1762-1777, 2020
• Meiffren G, Herbrand T, Anastassiadis E, Klein O, DeVries JH, Heise T, Alluis B, Megret C, Gaudier M, Soula O, Plum-Mörschel L.
  Better glycemic control with BioChaperone Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM).
  DIABETES OBES METAB 2019 Mar 3. doi: 10.1111/dom.13685. (Epub ahead of print)
• Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B.
  BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
  DIABETES OBES METAB 2018 Dec 18. doi: 10.1111/dom. 13621. (Epub ahead of print)
• Benesch C, Heise T, Klein O, Heinemann L, Arnolds S.
  How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device.
  J DIABETES SCI TECHNOL 9: 792-800, 2015.
• Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H.
  Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
  DIABETES OBES METAB 17: 659-664, 2015.
• Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H.Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus.
  DIABETES THER 5 (1): 255-265, 2014

Browse Oliver's entire list of publications or Profil's recent list of publications to see our other publications.

Selected Achievements and Work Experience